Acute-on-chronic liver failure: Current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 4, 2011, Pages 523-537

  Laleman, Wim ^a   Verbeke, Len ^a   Meersseman, Philippe ^a   Wauters, Joost ^a   Van Pelt, Jos ^a   Cassiman, David ^a   Wilmer, Alexander ^a   Verslype, Chris ^a   Nevens, Frederik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

cirrhosis; liver failure; liver support; multiorgan failure; portal hypertension

Indexed keywords

ACUTE ON CHRONIC LIVER FAILURE; ALBUMIN DIALYSIS; APACHE; BACTERIAL INFECTION; CLINICAL FEATURE; DIAGNOSTIC TEST; DIALYSIS EQUIPMENT AND SUPPLIES; DISEASE ASSOCIATION; DISEASE SEVERITY; END STAGE LIVER DISEASE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFECTION SENSITIVITY; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER INJURY; LIVER PARENCHYMA; LIVER TRANSPLANTATION; MORTALITY; PATHOGENESIS; PORTAL HYPERTENSION; PROGNOSIS; REVIEW; SINGLE PASS ALBUMIN DIALYSIS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT RESPONSE;

BACTERIAL INFECTIONS; BRAIN; DIALYSIS; END STAGE LIVER DISEASE; HUMANS; KIDNEY; LIVER CIRRHOSIS; LIVER FAILURE, ACUTE;

EID: 79960751593     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.47     Document Type: Review

References (106)

1. Laleman W, Wilmer A, Evenepoel P, Verslype C, Fevery J, Nevens F. Review article: non-biological liver support in liver failure. Aliment. Pharmacol. Ther. 23, 351-363 (2006). (Pubitemid 43382015)
2. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 20, 252-261 (2002). (Pubitemid 34195668)
3. Martin JA, Smith BL, Mathews TJ, Ventura SJ. Births and deaths: preliminary data for 1998. In: National Center for Health Statistics. National Vital Statistics Report. Vol. 47, No. 25. Hyattsville MD (Ed.).National Center for Health Statistics, USA (1998).
4. Kim WR, Brown RS Jr, Terrault NA, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 36, 227-242 (2002). (Pubitemid 34700782)
5. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 367, 52-56 (2006). (Pubitemid 43038670)
6. Roberts SE, Goldacre MJ, Yeates D. Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 54, 1615-1621 (2005). (Pubitemid 41531782)
7. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J. Hepatol. 40, 860-867 (2004). (Pubitemid 38507370)
8. Vilstrup H, Iversen J, Tygstrup N. Glucoregulation in acute liver failure. Eur. J. Clin. Invest. 16, 193-197 (1986). (Pubitemid 16096132)
9. Wanless IR, Wong F, Blendis LM et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 21, 1238-1247 (1995).
10. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124, 91-96 (2003). (Pubitemid 36055342)
11. Desschans B, Van Gelder F, Van Hees D et al. Evolution in allocation rules for renal, hepatic, pancreatic and intestinal graft. Acta Chir. Belg. 108, 31-34 (2008).
12. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int. J. Artif. Organs 19, 677-691 (1996). (Pubitemid 27006867)
13. Sen S, Williams R. New liver support devices in acute liver failure: a critical evaluation. Semin. Liver Dis. 23, 283-294 (2003). (Pubitemid 37052453)
14. Sen S, Ytrebo LM, Rose C et al. Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs. Intensive Care Med. 30, 496-501 (2004). (Pubitemid 38375628)
15. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am. J. Gastroenterol. 100, 468-475 (2005). (Pubitemid 40314536)
16. Stadlbauer V, Krisper P, Aigner R et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit. Care 10, R169 (2006).
17. Krisper P, Stauber RE. Technology insight: artificial extracorporeal liver support - how does Prometheus compare with MARS. Nat. Clin. Pract. Nephrol. 3, 267-276 (2007). (Pubitemid 46674520)
18. Sen S, Jalan R, Williams R. Liver failure: basis of benefit of therapy with the molecular adsorbents recirculating system. Int. J. Biochem. Cell Biol. 35, 1306-1311 (2003). (Pubitemid 36703169)
19. Abouna GM. Cross-circulation between man and baboon in hepatic coma. Lancet 2, 729-730 (1968).
20. Hoofnagle JH, Carithers RL Jr, Shapiro C, Asscher N. Fulminant hepatic failure: summary of a workshop. Hepatology 21, 240-252 (1995).
21. Losser MD, Payen D. Mechanisms of liver damage. Sem. Liver Dis. 16, 357-367 (1996). (Pubitemid 27074778)
22. Thalheimer U, Triantos CK, Samonakis DN. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 54, 556-563 (2005). (Pubitemid 40395508)
23. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin. Liver Dis. 28, 26-42 (2008). (Pubitemid 351326531)
24. Navasa M, Fernandez J, Rodes J. Bacterial infections in liver cirrhosis. Ital. J. Gasteroenterol. Hepatol. 31, 616-625 (1999). (Pubitemid 29527855)
25. Antoniades CG, Berry P, Wendon J. The importance of immune dysfunction in determining outcome in acute liver failure. J. Hepatol. 49, 845-861 (2008).
26. Rosenbloom AJ, Pinsky MR, Bryant JL. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 274, 58-65 (1995).
27. Lin CH, Tsai IF, Ho YP. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J. Hepatol. 46, 816-826 (2007).
28. Wasmuth HE, Kunz D, Yagmur E et al. Patients with acute on chronic liver failure display 'sepsis-like' immune paralysis. J. Hepatol. 42, 195-201 (2005). (Pubitemid 40143465)
29. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112, 235-243 (1997). (Pubitemid 27343624)
30. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J. Hepatol. 51, 475-482 (2009).
31. Bone R. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 24, 1125-1128 (1999).
32. Albillos A, Hera Ad Ade L, Reyes E et al. Tumour necrosis factor-a expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J. Hepatol. 40, 624-631 (2004). (Pubitemid 38367784)
33. Riordan SM, Skinner N, Nagree A et al. Peripheral blood mononuclear cell expression of toll-like receptors 2 and 4 in patients with liver cirrhosis. Hepatology 37, 1154-1164 (2003). (Pubitemid 36538693)
34. Leber B, Mayrhauser U, Rybczynski M, Stadlbauer V. Innate immune dysfunction in acute and chronic liver disease. Wien. Klin. Wochenschr. 121, 732-744 (2009).
35. Jaeschke H, Hasegawa T. Role of neutrophils in acute inflammatory liver injury. Liver Int. 26, 912-919 (2006). (Pubitemid 44323408)
36. Fiuza C, Salcedo M, Clemente G et al. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J. Infect. Dis. 182, 526-533 (2000). (Pubitemid 30651050)
37. Sarin SK, Kumar A, Almeida JA et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).Hepatol. Int. 3,269-282 (2009).
38. Katoonizadeh A, Laleman W, Verslype C et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 59, 1561-1569 (2010).
39. Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-hepatic insults are common precipitants in patients with acute on chronic liver failure (ACLF).Dig. Dis. Sci. 55, 3188-3192 (2010).
40. Karvellas CJ, Pink F, McPhail M et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage end liver disease are independent predictors of mortality in critically ill non-transplanted patients with acute on chronic liver failure. Crit. Care Med. 38, 121-126 (2010).
41. Aggarwal A, Ong JP, Younossi ZM, Nelson DR, Hoffman-Hogg L, Arroliga AC. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 119, 1489-1497 (2001). (Pubitemid 32686034)
42. Zimmerman JE, Wagner DP, Seneff MG et al. Intensive care unit admissions with cirrhosis: risk-stratifying patient groups and predicting individual survival. Hepatology 23, 1393-1401 (1996). (Pubitemid 26181221)
43. Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 34, 255-261 (2001). (Pubitemid 32702337)
44. Warrilow SJ. Predictions and outcomes for the critically ill patient with cirrhosis: is it time to settle on the SOFA and let jaundiced views on the outcome MELD away. Crit. Care Med. 38, 2259-2260 (2010).
45. Das V, Boelle PY, Galbois A et al. Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit. Care Med 38, 2108-2116 (2010).
46. Cholongitas E, Senzolo M, Patch D et al. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short-term mortality in cirrhotic patients admitted to intensive care unit. Aliment. Pharmacol. Ther. 23, 883-893 (2006).
47. Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Concensus Conference definitions of the systemic inflammatory response syndrome (SIRS) and allied disorders in relation to critically injured patients. Crit. Care Med. 25, 1789-1795 (1997). (Pubitemid 27483955)
48. Thabut D, Massard J, Gangloff A et al. Model for end-stage liver disease score andsystemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 46, 1872-1882 (2007).
49. Jalan R, Mookerjee RP. Acute-on-chronic liver failure: an early biopsy is essential? Gut 59, 1455-1456 (2010).
50. Laleman W, Van Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int. 25, 1079-1090 (2005). (Pubitemid 41782549)
51. Laleman W. Role of vasoactive substances and cellular effectors in the pathophysiology of cirrhotic portal hypertension: the past, the present and the future - Georges Brohée lecture. Acta Gastroenterol. Belg. 72, 9-16 (2009).
52. Bosch J, Garcia Pagan JC. Complications of cirrhosis. I. Portal hypertension. J. Hepatol. 32(Suppl. 1), 141-156 (2000).
53. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Light and shadows in an important clinical problem. J. Hepatol. 32(Suppl. 1), 157-170 (2000). (Pubitemid 30123632)
54. Fernandez Seara J, Prieto J, Quiroga J et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97, 1304-1312 (1989). (Pubitemid 19258718)
55. Maroto A, Gines P, Arroyo V et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 17, 788-793 (1993). (Pubitemid 23150086)
56. Rivolta R, Maggi A, Cazzaniga M et al. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology 28, 1235-1240 (1998). (Pubitemid 28493832)
57. Guevara M, Bru C, Gines P et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 2, 839-844 (1998).
58. Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 17, 219-224 (1993). (Pubitemid 23046692)
59. Sugano S, Yamamoto K, Atobe T et al. Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients. A placebo, controlled evaluation. J. Hepatol. 34, 373-377 (2001). (Pubitemid 32240815)
60. Dillon JF, Plevris JN, Wong FC et al. Middle cerebral artery blood flow velocity in patients with cirrhosis. Eur. J. Gastroenterol. Hepatol. 7, 1087-1091 (1995). (Pubitemid 26014465)
61. Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment. Pharmacol. Ther. 16(Suppl. 5), 12-23 (2002). (Pubitemid 41759558)
62. Llach J, Gines P, Arroyo V et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 94, 482-487 (1998).
63. Laleman W. Hemodynamic effects of albumin dialysis in patients with liver failure: for better or for worse? Ther. Apher. Dial. 13, 384-392 (2009).
64. Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl. 7, 1034-1039 (2001). (Pubitemid 34023990)
65. Laleman W, Wilmer A, Evenepoel P et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit. Care 10(4), R108 (2006).
66. Ruiz del Arbol L. Urman J, Fernandez J et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38, 1210-1218 (2003). (Pubitemid 37314829)
67. Ruiz del Arbol L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42, 439-447 (2005). (Pubitemid 41061097)
68. Ma ZH, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 24, 451-459 (1996). (Pubitemid 26260046)
69. Marik P, Gayowski T, Starzi T; Hepatic Cortisol Research and Adrenal Pathophysiology Study Group. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit. Care Med. 33, 1254-1259 (2003).
70. Tsai MH, Peng YS, Chen YC et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 43, 673-681 (2006).
71. Fernández J, Escorsell A, Zabalza M et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 44, 1288-1295 (2006). (Pubitemid 44748379)
72. O'Beirne J, Holmes M, Agarwal B et al. Adrenal insufficiency in liver diease - what is the evidence? J. Hepatol. 47, 418-423 (2007). (Pubitemid 47176168)
73. Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int. 23, 71-77 (2003). (Pubitemid 37265777)
74. Moreau R, Lebrec D. Acute kidney injury: new concepts. Hepatorenal syndrome: the role of vasopressors. Nephron. Physiol. 109, 73-79 (2008).
75. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56, 1310-1318 (2007). (Pubitemid 47300435)
76. Salerno F, Guevara M, Bernardi M et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 30, 937-947 (2010).
77. Gines A, Escorsell A, Gines P et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105, 229-236 (1993). (Pubitemid 23234041)
78. Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J. Clin. Invest. 46, 1894-1806 (1967).
79. Moller S, Dumcke CW, Krag A. The heart and the liver. Expert Rev. Gastroenterol. Hepatol. 3, 51-64 (2009).
80. Bleck TP, Smith MC, Pierre-Louis SJ, Jares JJ, Murray J, Hansen CA. Neurologic complications of critical medical illnesses. Crit. Care Med. 21, 98-103 (1993). (Pubitemid 23028482)
81. Cordoba J, Garcia-Martinez R, Simon- Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab. Brain Dis. 25, 73-80 (2010).
82. Fichet J, Mercier E, Genee O et al. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J. Crit. Care 24, 364-370 (2009).
83. Borzio M, Salerno F, Piantoni L et al. Bacterial infections in patients with advanced cirrhosis: a multicentric prospective study. Dig. Liver Dis. 33, 41-48 (2001). (Pubitemid 32186174)
84. Fernandez J, Navasa M, Gomez J et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35, 140-148 (2002). (Pubitemid 34032554)
85. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the national hospital discharge survey. Chest 124, 1016-1020 (2003). (Pubitemid 37123324)
86. Meerseman W, Vandecasteele SJ, Wilmer A, Verbeken A, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am. J. Respir. Crit. Care Med. 170, 621-625 (2004). (Pubitemid 39202203)
87. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif. Organs 17, 809-813 (1993). (Pubitemid 23288693)
88. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int. J. Artif. Organs 19, 677-691 (1996). (Pubitemid 27006867)
89. Rifai K, Ernst T, Kretschmer U et al. Prometheus - a new extracorporeal system for the treatment of liver failure. J. Hepatol. 39, 984-990 (2003). (Pubitemid 37523770)
90. Peszynski P, Klammt S, Peters E et al. Albumin dialysis: single pass vs recirculation (MARS).Liver 22(Suppl. 2), 40-42 (2002).
91. Chawla LS, Georgescu F, Abell B et al. Modification of continuous venovenous hemodiafiltration with single-pass albumin dialysate allows for removal of serum bilirubin. Am. J. Kidney Dis. 45, 51-56 (2005).
92. Sauer IM, Goetz M, Steffen I et al. In vitro comparision of the molecular adsorbent recirculation system and single-pass albumin dialysis (SPAD).Hepatology 39, 1408-1414 (2004). (Pubitemid 38569063)
93. Kortgen A, Rauchfuss F, Götz M et al. Albumin dialysis in liver failure: comparison of molecular adsorbent recirculating system and single pass albumin dialysis - a retrospective analysis. Ther. Apher. Dial. 13, 419-425 (2009).
94. Al-Chalabi A, Matevossian E, Preissel AK et al. Survival improvement in pigs with liver failure and superimposed sepsis by a new liver support system (Hepa Wash®).Critical Care 14, P508 (2010).
95. Stadlbauer V, Davies NA, Sen S, Jalan R. Artificial liver support systems in the management of complications of cirrhosis. Semin. Liver Dis. 28, 96-109 (2008). (Pubitemid 351326536)
96. Stange J, Mitzner SR, Risler T et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif. Organs 23, 319-330 (1999). (Pubitemid 29200993)
97. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extra-corporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J. Hepatol. 38, 24-31 (2003). (Pubitemid 36078520)
98. Di Campli C, Zocco MA, Gaspari R et al. The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant. Proc. 37, 2551-2553 (2005). (Pubitemid 41354666)
99. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 6, 277-286 (2000). (Pubitemid 30317221)
100. Heemann U, Treichel U, Loock J et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36, 949-958 (2002).
101. Sen S, Davies NA, Mookerjee RP et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 10, 1109-1119 (2004). (Pubitemid 39248408)
102. Hassanein TI, Tofteng F, Brown RS Jr et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46, 1853-1862 (2007).
103. Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl. 10, 1099-1106 (2004). (Pubitemid 39248406)
104. Liu JP, Gluud LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure. Cochrane Database Syst. Rev. 1, CD003628 (2004).
105. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M; RELIEF study group. Extracorporeal liver support with MARS in patients with acute-on-chronic liver failure. The RELIEF trial. J. Hepatol. 52, S459 (2010).
106. Rifai K, Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U; HELIOS-study group. Extracorporeal liver support by fractionated plasma separation and absorption (Prometheus) in patients with acute-on-chronic liver failure (HELIOS study): a prospective randomized controlled multicenter study. J. Hepatol. 52, S3 (2010).